TSW
ANIK icon

Thompson Siegel & Walmsley’s Anika Therapeutics ANIK Stock Holding History

Thompson Siegel & Walmsley’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1
Closed – – 650
2019
Q4 		$0 Sell
1
-70
-99% -$4.07K ﹤0.01% 791
2019
Q3 		$4K Sell
71
-48,531
-100% -$2.49M ﹤0.01% 692
2019
Q2 		$1.97M Sell
48,602
-10,410
-18% -$380K 0.03% 206
2019
Q1 		$1.78M Buy
59,012
+3,840
+7% +$132K 0.03% 215
2018
Q4 		$1.85M Buy
55,172
+29,685
+116% +$1.07M 0.03% 207
2018
Q3 		$1.07M Buy
+25,487
New +$1.01M 0.01% 299
2017
Q4 		– Sell
-66
Closed -$4K – 828
2017
Q3 		$4K Sell
66
-196,016
-100% -$10.2M ﹤0.01% 791
2017
Q2 		$9.68M Sell
196,082
-84,720
-30% -$3.9M 0.11% 192
2017
Q1 		$12.2M Sell
280,802
-217,661
-44% -$10.4M 0.14% 177
2016
Q4 		$24.4M Sell
498,463
-95,075
-16% -$4.4M 0.32% 96
2016
Q3 		$28.4M Sell
593,538
-6,993
-1% -$345K 0.44% 81
2016
Q2 		$32.2M Sell
600,531
-162,265
-21% -$7.65M 0.51% 69
2016
Q1 		$34.1M Sell
762,796
-213,704
-22% -$8.67M 0.55% 68
2015
Q4 		$37.3M Sell
976,500
-102,602
-10% -$3.92M 0.67% 40
2015
Q3 		$34.3M Buy
1,079,102
+32,349
+3% +$1.13M 0.64% 46
2015
Q2 		$34.6M Buy
1,046,753
+368,395
+54% +$13.1M 0.61% 44
2015
Q1 		$27.9M Buy
678,358
+21,328
+3% +$862K 0.48% 66
2014
Q4 		$26.8M Buy
657,030
+60,788
+10% +$2.38M 0.51% 60
2014
Q3 		$21.9M Buy
596,242
+332,620
+126% +$14.4M 0.44% 78
2014
Q2 		$12.2M Buy
263,622
+262,822
+32,853% +$11.7M 0.24% 180
2014
Q1 		$33K Hold
800
– – ﹤0.01% 491
2013
Q4 		$31K Hold
800
– – ﹤0.01% 491
2013
Q3 		$19K Hold
800
– – ﹤0.01% 521
2013
Q2 		$14K Buy
+800
New +$11.5K ﹤0.01% 551

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Thompson Siegel & Walmsley's ANIK Position: Q1 2020 in Review

Thompson Siegel & Walmsley sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 1 share.

Thompson Siegel & Walmsley first reported a position in ANIK in Q2 2013 and held it in 24 quarters. The position peaked at $37.3M in Q4 2015. 163 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

  • Thompson Siegel & Walmsley reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 1 Anika Therapeutics share in Q1 2020.
  • Thompson Siegel & Walmsley first reported a position in Anika Therapeutics in Q2 2013 and held it in 24 quarters.
  • Thompson Siegel & Walmsley's Anika Therapeutics position peaked at $37.3M in Q4 2015.
  • 163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2020, filed 12 May 2020.